ZOvCa - A phase 1 PET-CT study of 89Zr-hu/mo-10D7 in patients with advanced epithelial Ovarian Cancer
The research team have developed a protein, called an antibody, that binds selectively to epithelial ovarian cancer cells. The antibody is labelled with a radioactive metal ion, the weak signal from which can be detected on a Positron Emission Tomography (PET) scan. The PET scan will show the medical team where cancer cells are within the body.
What you need to know
Who can take part
The trial is seeking:
- Adults (≥ 18 years)
- Histologically proven advanced ovarian cancer
What is involved for you
If you are a Mater patient, screening will take place at Mater Hospital Brisbane. All other visits will be conducted at the Royal Brisbane and Women’s Hospital.
If you are a Royal Brisbane and Women’s Hospital (RBWH) patient, all visits will be conducted at RBWH.
Your study doctor and/or a member of the research team will be scheduling your visits and you will be informed well ahead of time.
This study consists of the following hospital visits:
- Screening (up to 30 days prior to injection of the imaging agent)
- Day 0: Injection of the imaging agent, imaging, and assessments (duration approximately six hours)
- Day 2 ± 1 day: Imaging (duration approximately two hours)
- Day 5 ± 1 day : Imaging and assessments (duration approximately four hours)
- Day 7 ± 1 day: Imaging and assessments (duration approximately four hours)
Trial dates
September 2024 to September 2026
